American Healthcare REIT enters the back half of August with a striking contradiction: short interest jumping 36% in a single week while every analyst who touched the stock this month raised their price target.
The short-side surge is the week's defining tension. Short interest climbed from roughly 17.8 million shares to 24.2 million — a 36% week-on-week jump that pushed the SI level to 13.7% of the free float. That's a meaningful position in a healthcare REIT. The move happened in a compressed window: most of the build landed between August 10 and 11, lifting shorts from a relatively steady ~17.5 million shares held through late July into genuinely elevated territory. Despite that pile-on, the borrow market is not stressed. Cost to borrow is running at just 0.47%, barely above what it cost to short the stock a month ago. Availability is wide — roughly 498% of current short interest — meaning lenders have nearly five times as many shares available as are currently borrowed. The borrow story is far from tight.
Options positioning tells a sharply different story from the short sellers. The put/call ratio has collapsed to 0.05 — the lowest reading of the past 52 weeks, and nearly 1.7 standard deviations below the 20-day mean of 0.20. That's an unusually one-sided call-heavy setup. The options market is not hedging against downside; it's leaning aggressively bullish at the exact moment short sellers are rebuilding. That divergence rarely resolves quietly.
The Street is firmly in the bull camp. Every analyst move in the past week has been a target raise with a maintained positive rating: Keybanc lifted to $68, Citigroup moved to $65, and RBC and Truist both raised to $61 — all within the past five days. The mean price target now sits at $63.67 against a current price of $54.42, implying roughly 17% upside on the Street consensus. The analyst recommendation factor ranks in the 93rd percentile of the ORTEX universe, a near-top-of-the-range reading. Bulls point to a projected two-year CAGR of 11.8% in seniors housing and skilled nursing, plus aggressive capital deployment as the cost-of-capital picture improves. Bears counter that skilled nursing concentration carries real regulatory and reimbursement risk, and that an EV/EBITDA above 21 — down about 2 points over the past month as valuation has compressed slightly — leaves limited room for setbacks. The dividend score ranks in the 76th percentile, supporting income-oriented holders.
Institutional ownership adds another layer of conviction on the long side. BlackRock is the largest holder at 11.2% of shares and added 774,000 shares as recently as July 31. Principal Global Investors added nearly 1.5 million shares in the last reported period, and CenterSquare, a specialist REIT manager, added close to 1.4 million. That's a broad group of investors adding exposure through the summer, not trimming. The CEO's July 21 open-market sales of roughly $5 million — following concurrent award grants — read more as routine compensation-linked selling than a bearish signal, particularly given the scale of institutional inflows.
The stock gained 3.3% on the week to close at $54.42, broadly in line with its healthcare REIT peers: WELL rose 4.2% and VTR 4.9% over the same stretch, while CTRE added 1.6%. AHR is keeping pace with the sector recovery but has pulled back 4.8% over the past month, creating the gap that analysts are now flagging as opportunity. The next scheduled earnings event is November 6, giving the short-versus-analyst standoff more than two months to develop before a fundamental resolution arrives.
The key question between now and November is whether the fresh short interest represents informed positioning ahead of a specific catalyst — or whether it's a tactical trade into a liquid name that will need to cover as the analyst target-raise cycle continues and the borrow remains cheap and plentiful.
See the live data behind this article on ORTEX.
Open AHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
